CS logo
small CS logo
Institutul National de Boli Infectioase Prof.Dr.Matei Bals

Bucuresti, Romania
Institut de cercetare din Bucuresti

About Institutul National de Boli Infectioase Prof.Dr.Matei Bals


Institutul Național de Boli Infecțioase „Prof. Dr. Matei Balș” este un spital din București. Până în 1999 a purtat numele Spitalul Clinic de Boli Infecțioase Colentina. Din martie 1999, prin ordin al Ministerului Sănătății, Spitalul Clinic de Boli Infecțioase Colentina a devenit Institutul de Boli Infecțioase Prof.
  • Top Sponsors
  • Top Collaborators
  • Trials By Phase
  • Recruitment Status
  • Top Conditions
  • Intervention Types
  • Top Intervention Names
  • Trials By Gender
Lead Sponsor
# Trials
Gilead Sciences
6
Biolex Therapeutics, Inc.
2
Hoffmann-La Roche
2
Pfizer
2
Bayer
1
Boehringer Ingelheim
1
Eiger BioPharmaceuticals
1
Genfit
1
Novartis Pharmaceuticals
1
PharmaMar
1
Total Rows: 10

Clinical Trials at Institutul National de Boli Infectioase Prof.Dr.Matei Bals


During the past decade, Institutul National de Boli Infectioase Prof.Dr.Matei Bals conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 8 clinical trials were completed, i.e. on average, 114.3% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 2 clinical trials were completed. i.e. 100% of trials that started reached the finish line.
Created with Highcharts 11.1.0TrialsTrials Trend - Last 10 Years221122001111222200110011Started TrialsCompleted Trails2016201720182019202020210123
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.
2004-02-01
Terminated
562
Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV
2009-03-01
2011-11-01
Completed
116
480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV)
2009-07-01
2011-01-01
Completed
74
An Observational Cohort Study in Patients With Chronic Hepatitis B Receiving Pegasys
2009-04-11
2014-11-18
Completed
1,842
Epidemiological Study in Children and Adolescents With Chronic Hepatitis B
2009-06-01
Completed
1,640
Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B
2011-04-01
2015-07-01
Completed
751
A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treatment With Pegasys (Peginterferon Alfa-2a) ± Nucleoside/Nucleotide Analogue
2013-08-20
2014-11-28
Completed
1,669
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B
2013-09-01
2022-08-31
Completed
426

Rows per page:

1–18 of 18

Clinical Trials Sponsors and Collaborators


Out of the total clinical trials conducted in "Institutul National de Boli Infectioase Prof.Dr.Matei Bals" #1 sponsor was "Gilead Sciences" with 6 trials, followed by "Biolex Therapeutics, Inc." with 2 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored, "Pfizer" with 2 trials sponsored and "Bayer" with 2 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Institutul National de Boli Infectioase Prof.Dr.Matei Bals" #1 collaborator was "Allergan" with 1 trials as a collaborator, "Biomedical Advanced Research and Development Authority" with 1 trials as a collaborator and "Innovative Medicines Initiative (IMI) COMBACTE-CARE (EU)" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.
Created with Highcharts 11.1.0Top Leading SponsorsGilead Sciences: 6Gilead Sciences: 6Biolex Therapeutics, Inc.: 2Biolex Therapeutics, Inc.: 2Hoffmann-La Roche: 2Hoffmann-La Roche: 2Pfizer: 2Pfizer: 2Bayer: 1Bayer: 1Boehringer Ingelheim: 1Boehringer Ingelheim: 1Eiger BioPharmaceuticals: 1Eiger BioPharmaceuticals: 1Genfit: 1Genfit: 1Novartis Pharmaceuticals: 1Novartis Pharmaceuticals: 1PharmaMar: 1PharmaMar: 1

Created with Highcharts 11.1.0Top CollaboratorsAllergan: 1Allergan: 1Biomedical AdvancedResearch andDevelopment Authority:1Biomedical AdvancedResearch andDevelopment Authority:1Innovative MedicinesInitiative (IMI)COMBACTE-CARE (EU):1Innovative MedicinesInitiative (IMI)COMBACTE-CARE (EU):1

Clinical Trials Conditions at Institutul National de Boli Infectioase Prof.Dr.Matei Bals


According to Clinical.Site data, the most researched conditions in "Institutul National de Boli Infectioase Prof.Dr.Matei Bals" are "Chronic Hepatitis B" (3 trials), "Hepatitis B, Chronic" (3 trials), "HBV" (2 trials), "Hepatitis C, Chronic" (2 trials) and "COVID-19 Infection" (1 trials). Many other conditions were trialed in "Institutul National de Boli Infectioase Prof.Dr.Matei Bals" in a lesser frequency.

Clinical Trials Intervention Types at Institutul National de Boli Infectioase Prof.Dr.Matei Bals


Most popular intervention types in "Institutul National de Boli Infectioase Prof.Dr.Matei Bals" are "Drug" (16 trials), "Biological" (1 trials) and "Combination Product" (1 trials). Other intervention types were less common.
The name of intervention was led by "TAF" (3 trials), "TDF" (3 trials), "ATM-AVI" (2 trials), "Placebo" (2 trials) and "Remdesivir" (2 trials). Other intervention names were less common.

Clinical Trials Genders at Institutul National de Boli Infectioase Prof.Dr.Matei Bals


The vast majority of trials in "Institutul National de Boli Infectioase Prof.Dr.Matei Bals" are 18 trials for "All" genders.

Clinical Trials Status at Institutul National de Boli Infectioase Prof.Dr.Matei Bals


Currently, there are NaN active trials in "Institutul National de Boli Infectioase Prof.Dr.Matei Bals". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Institutul National de Boli Infectioase Prof.Dr.Matei Bals, undefined suspended trials, and 4 terminated clinical trials to date.
Out of the total trials that were conducted in Institutul National de Boli Infectioase Prof.Dr.Matei Bals, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".
Created with Highcharts 11.1.0Trials By PhasePhase 3: 7Phase 3: 7Phase 2: 5Phase 2: 5Phase 1: 1Phase 1: 1Phase 4: 1Phase 4: 1

Created with Highcharts 11.1.0Trials StatusCompleted: 12Completed: 12Terminated: 4Terminated: 4Approved for marketing: 1Approved for marketing: 1Recruiting: 1Recruiting: 1